Keely Beck Zipp

VP, Commercial Strategy & Innovation, Rare Disease at Pfizer

Keely Beck Zipp has extensive experience in the pharmaceutical industry, having held various roles in companies such as Pfizer, Lava Therapeutics B.V., Cybrexa Therapeutics, Incyte, GSK, Wyeth Pharmaceuticals, and Strategic Decisions Group.

Notably, Keely served as the Vice President of Commercial Strategy and Innovation for Non-Malignant Hematology at Pfizer since 2022. Keely Beck also worked as a Strategic Advisor at Stark Strategic Advisors LLC from 2022 to 2022.

In their previous roles, Keely held key positions such as VP of Corporate Development and Portfolio Strategy at Lava Therapeutics B.V., SVP of Corporate Development and Commercial Strategy at Cybrexa Therapeutics, and Sr. Director of Global Strategic Planning and Corporate Operations at Incyte.

Before that, they held various roles at GSK, including Global Marketing Manager for Oncology, Director of Global Oncology Franchise Operations, Commercial Director for Global Medicines Futures, and Manager of Business and Commercial Analysis in Oncology.

Prior to joining GSK, Keely worked as a Manager of Global Business Development, Mergers & Acquisitions at Wyeth Pharmaceuticals. Keely Beck started their career as a Consultant at Strategic Decisions Group, where they led a team focused on alternative strategies for entering the protein therapeutics business.

Throughout their career, Keely has demonstrated expertise in areas such as commercial strategy, corporate development, portfolio strategy, strategic planning, business analysis, and marketing.

Keely Beck Zipp obtained a Master of Business Administration (M.B.A.) degree with a focus on Finance and Health Care Management from The Wharton School, where they attended from 2006 to 2008. Prior to that, they pursued their undergraduate studies in Biochemistry at Dartmouth College from 1998 to 2002, earning a Bachelor of Arts (BA) degree.

Links

Previous companies

Incyte logo
Cybrexa Therapeutics logo
Strategic Decisions Group (SDG) logo
Lava Therapeutics B.V. logo

Timeline

  • VP, Commercial Strategy & Innovation, Rare Disease

    December, 2022 - present

View in org chart